Q-omics provides the consensus-scored KRTAP4-17P profile across patient tissues and cancer cell-line models. KRTAP4-17P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRTAP4-17P is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, KRTAP4-17P RNA expression shows 4,147 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where KRTAP4-17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP4-17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP4-17P survival associations across molecular data types. KRTAP4-17P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP4-17P RNA expression–survival associations across cancer types. High KRTAP4-17P expression shows unfavorable associations in KIRC, BLCA, KIRP, LIHC, TGCT and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRTAP4-17P RNA expression.
This table summarizes KRTAP4-17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP4-17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP4-17P shows higher tumor expression in HNSC, LUAD, LUSC, BLCA, STAD and COAD. The HNSC box plot shows higher KRTAP4-17P RNA expression in tumor versus normal tissue (log2 FC = +0.313, t-test p < 0.001).
This table shows molecular features associated with KRTAP4-17P in patient tissues and cancer cell lines. In patient samples, KRTAP4-17P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
